Objectif The objective of ExCellENT-HIT is the exploitation of the cellular pathways responsible for the nuclear export of unprocessed HIV-1 transcripts, as a novel anti-HIV therapeutic strategy. Our approach is innovative, the objectives are very clear and focused, and achievable within two years. Combination therapies with drugs targeting viral proteins are the current standard of care for HIV-1 infections. However, drug resistant strains emerge, resulting in therapeutic failure. Consequently, new anti-HIV drugs are needed, which should represent novel chemical entities targeting new steps of the HIV replication cycle. Viruses need the host cellular metabolism in order to generate a progeny. By targeting cellular co-factors essential for HIV replication and whose inhibition is not harming the uninfected cells, drug resistance is less likely to occur. Nuclear export of unspliced viral RNAs is an essential step of the HIV life cycle, regulated by the viral protein Rev. Compelling experimental evidence recently identified the cellular DEAD-box RNA helicase DDX3 as an essential cofactor for viral mRNA export. Therefore, we seek to inhibit the nuclear export of unspliced viral RNAs activity by a 'two hit strategy' targeting the cellular enzyme DDX3 and the viral protein Rev, thereby minimizing the appearance of drug resistance HIV mutants. Basic science, biotechnology and provocative chemistry, will integrate with the ultimate goal of targeting the Rev/DDX3 axis by the identification of molecular decoys that inhibit DDX3 helicase activity, Rev/DDX3 nuclear export and protein-protein interaction required for Rev/DDX3 function. The knowledge and technology generated in this project on therapeutic targeting of nuclear export, protein-protein interaction and helicase activity is likely to cumulate in hit discovery and will have a wide applicability in the pharmaceutical industry.' Champ scientifique sciences médicales et de la santémédecine fondamentalepharmacologie et pharmaciedécouverte de médicamentssciences naturellessciences biologiquesbiochimiebiomoléculeprotéinesprotéomiquesciences médicales et de la santésciences de la santémaladie infectieusevirus à ARNVIHsciences médicales et de la santémédecine fondamentalepharmacologie et pharmacierésistance aux médicamentssciences naturellessciences biologiquesgénétiqueARN Programme(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Thème(s) LSH-2005-2.3.0-4 - New approaches for research into host/vector-pathogen interaction for HIV/AIDS, malaria and tuberculosis Appel à propositions FP6-2005-LIFESCIHEALTH-6 Voir d’autres projets de cet appel Régime de financement STREP - Specific Targeted Research Project Coordinateur KATHOLIEKE UNIVERSITEIT LEUVEN Adresse Oude markt 13 Leuven Belgique Voir sur la carte Liens Site web Opens in new window Contribution de l’UE € 0,00 Participants (5) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire CONSIGLIO NAZIONALE DELLE RICERCHE Italie Contribution de l’UE € 0,00 Adresse Piazzale aldo moro 7 Rome Voir sur la carte Liens Site web Opens in new window CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS Allemagne Contribution de l’UE € 0,00 Adresse Paul-ehrlich-str. 42-44 Frankfurt am main Voir sur la carte Liens Site web Opens in new window JOHANNES GUTENBERG-UNIVERSITÄT MAINZ Allemagne Contribution de l’UE € 0,00 Adresse Saarstrasse 21 Mainz Voir sur la carte Liens Site web Opens in new window UNIVERSITÀ DEGLI STUDI DI SIENA Italie Contribution de l’UE € 0,00 Adresse Banchi di sotto 55 Siena Voir sur la carte Liens Site web Opens in new window UNIVERSITÄTSKLINIKUM HEIDELBERG Allemagne Contribution de l’UE € 0,00 Adresse Im neuenheimer feld 672 Heidelberg Voir sur la carte Liens Site web Opens in new window